Insights

DALLAS, TX – June 11, 2024 – Pharmaceutical Strategies Group (“PSG”), an EPIC company, released its annual Trends in Drug Benefit…

Plan sponsors face an increasingly complex challenge: effectively managing the high costs of innovative and life-changing medications while providing appropriate treatments for their employees…

Gain insights into biosimilar strategies from our 2024 Trends in Specialty Drug Benefits Report On April 29th, we released our highly anticipated 2024…

Reprinted with AIS Health permission from the May 2024 issue of Radar on Specialty Pharmacy. Rebates continue to be a huge part of…

Medicare drug price negotiation, impacts and considerations for plans Several months ago, I wrote a blog about the Medicare Drug…

GLP-1s Are Effective Solutions For Managing Diabetes, But Are Only One Piece of the Puzzle With all the talk about GLP-1s for weight loss,…

DALLAS, TX – May 6, 2024 – Pharmaceutical Strategies Group (“PSG”), an EPIC company, has added two…

PSG announces the results of its extensive research on the latest trends in drug benefit design. Plan sponsors face complex decisions and challenges…

The AMP Cap Has Lowered Insulin’s Price, Affecting Rebate Payments to Plan Sponsors. In June 2023, I published a blog…